Relationship Between Neck Circumference and Cardiometabolic Parameters in HIV-Infected and non–HIV-Infected Adults

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation       | Fitch, Kathleen V., Takara L. Stanley, Sara E. Looby, Alison M. Rope, and Steven K. Grinspoon. 2011. Relationship between neck circumference and cardiometabolic parameters in HIV-infected and non–HIV-infected adults. Diabetes Care 34(4): 1026-1031. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Published Version | doi:10.2337/dc10-1983                                                                                                                                                                                                                                                                                                         |
| Citable link    | http://nrs.harvard.edu/urn-3:HUL.InstRepos:9809493                                                                                                                                                                                                                                                                              |
| Terms of Use    | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA                                                                                                                                 |

Relationship Between Neck Circumference and Cardiometabolic Parameters in HIV-Infected and Non–HIV-Infected Adults

Kathleen V. Fitch, MSN
Takara L. Stanley, MD
Sara E. Looby, PhD

Alison M. Rope, AB
Steven K. Grinspoon, MD

OBJECTIVE—Upper body fat is associated with increased cardiometabolic risk. More recently, neck circumference (NC) and/or neck fat have been associated with hyperlipidemia, impaired glucose homeostasis, and hypertension. The objective of this study was to determine whether this relationship is evident in HIV-infected individuals, who often exhibit changes in relative fat distribution, and to determine whether NC is independently associated with carotid intima-media thickness (cIMT) in HIV and non–HIV-infected patients.

RESEARCH DESIGN AND METHODS—Body composition, including anthropometrics, visceral adipose tissue assessment by CT, and metabolic parameters, including lipids, cIMT, and oral glucose tolerance test, were measured in 174 men and women with HIV infection and 154 non–HIV-infected subjects. NC was measured in triplicate inferior to the laryngeal prominence.

RESULTS—In univariate analysis, NC was significantly and positively related to blood pressure, hemoglobin A1c, glucose, and insulin and significantly and negatively related to HDL cholesterol in HIV-infected individuals and HIV-negative control subjects. NC was significantly associated with cIMT in univariate regression analysis among HIV-infected (r = 0.21, P = 0.006) and non–HIV-infected (r = 0.31, P = 0.001) patients. This relationship remained significant among non–HIV-infected patients (r² = 0.45, P < 0.001) but not HIV-infected patients in multivariate modeling controlling for age, sex, race, smoking, hypertension, glucose, and lipids.

CONCLUSIONS—Among both HIV and non–HIV-infected patients, increased NC is strongly associated with decreased HDL and impaired glucose homeostasis. Among non–HIV-infected subjects, NC also predicts increased cIMT when controlling for traditional risk factors.

Diabetes Care 34:1026–1031, 2011

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in the U.S. In HIV disease, CVD is more prevalent than in the general population (1). Adiposity is a well known risk factor for cardiovascular morbidity, and recent research highlights the cardiovascular risk conferred by specific patterns of fat distribution, particularly visceral and upper body adiposity (2,3). The role of body fat distribution is of particular importance in HIV infection, because over half of infected individuals experience peripheral fat atrophy and/or increased central adiposity. Body fat redistribution may be related to HIV itself but is more commonly related to antiretroviral (ARV) medications, traditional CVD risk factors, and poor lifestyle habits (4,5). The cardiometabolic risk conferred by increased visceral fat in HIV infection has been well characterized (6,7). Upper trunk fat has also been identified as a strong determinant of insulin resistance in this population (8); however, neck circumference (NC) has not been investigated. In the non–HIV-infected population, a recent study looking at NC concluded that NC is associated with CVD risk factors even after adjustment for visceral adipose tissue (VAT) and BMI (9). In this study, we sought to examine NC among HIV-infected and non–HIV-infected men and women to determine whether NC independently relates to cardiometabolic risk controlling for BMI and more sophisticated measurements of adiposity. Furthermore, we sought for the first time to investigate the association of NC to subclinical atherosclerosis as measured by carotid intima-media thickness (cIMT).

RESEARCH DESIGN AND METHODS—Data were collected from 2000 to 2007 in 174 HIV-infected subjects at the Massachusetts General Hospital (MGH) and the Massachusetts Institute of Technology (MIT), and 154 HIV-negative subjects simultaneously recruited based on similar criteria. The subjects in this study comprise a convenience cohort for the purposes of the current analysis, consisting of baseline data collected for two observational studies, in which NC and cIMT data were available in HIV-infected and BMI, age, and race-matched non–HIV-infected control subjects recruited based on similar criteria. The first cohort recruited consisted of HIV-infected women and female control subjects, whereas the second cohort consisted of HIV and non–HIV-infected men and women. For each study, consecutive HIV-infected subjects between 18 and 65 years of age were enrolled without regard to fat distribution. Subjects in both the HIV and non–HIV groups were excluded if they had a known history of diabetes; were receiving insulin, antidiabetic agents,
glucocorticoids, growth hormone, supraphysiological testosterone replacement, or anabolic steroids; or were pregnant or breastfeeding within the past year. Partial data on 199 patients were published previously (10) but did not include an analysis of NC. All participants provided informed consent. The studies were approved by the Institutional Review Boards at both the MGH and MIT.

**Body composition**

Weight and anthropometric measurements were determined before breakfast. All measurements were obtained using a nonelastic tape; measurements were obtained in triplicate and then averaged. NC was obtained with the subject sitting with head in the Frankfort Horizontal Plane position. A measuring tape was applied around the neck inferior to the laryngeal prominence and perpendicular to the long axis of the neck, and the minimal circumference was measured and recorded to the nearest 0.1 cm. Intrusubject variability in the NC measurement was examined, and the difference between maximal and minimal measures averaged 0.3%. Waist, hip, arm, and chest circumferences were determined. To assess abdominal visceral and subcutaneous adipose tissue area (VAT and SAT, respectively), a cross-sectional abdominal CT scan at the level of the L4 pedicle was performed (11). Dual X-ray absorptiometry to assess body fat composition was performed using a Hologic densitometer (Hologic, Waltham, MA). In one of the cohorts, physical activity was assessed using the Modifiable Activity Questionnaire (12).

**cIMT**

Imaging was conducted using a 7.5-MHz phased-array transducer (SONOS 2000/2500; Hewlett-Packard, Andover, MA) as described previously (13). The published reproducibility of the technique is excellent with a SD of 0.007 mm (13). The cIMT over the length of the left and right segments was averaged. Although there were no statistical differences between left and right cIMT measurements, with a good univariate correlation between the two sides (r = 0.65, P < 0.001), there was some intrasubject variability of left and right cIMT measurements because of the focal nature of atherosclerosis. Average cIMT was used to reduce variability of this measurement, as reported in prior studies, such as the Atherosclerosis Risk in Communities Study (ARIC) cohort (14). To determine whether increasing neck size affected the variability of the cIMT measurement, we assessed the variance of cIMT across quartiles of NC. The SEM for the lowest quartile was 0.014, and the SEM for the highest quartile was 0.014, suggesting minimal change in variance in our cIMT data with increasing NC.

**Biochemical indexes**

Fasting insulin, glucose, triglycerides, cholesterol, HDL cholesterol, LDL cholesterol, and CD4 were measured using standard techniques. HIV testing was performed by chemiluminescent immunoassay and confirmed by Western blot. HIV viral load was measured using ultrasensitive assay.

A 75-g oral glucose tolerance test (OGTT) was performed after a 12-h overnight fast.

**Statistical analysis**

Comparison of demographic variables was made using Student t test for continuous variables and the χ² test for noncontinuous variables. Pearson correlation coefficients were assessed in univariate analysis. Multivariate regression analysis using standard least squares was performed. All multivariate analyses controlled for age, sex, race, and HIV status. Cumulative exposure to ARVs by class, e.g., nucleoside reverse transcriptase inhibitor (NRTI), was used when examining the effect of ARVs. In multivariate modeling for cIMT, there was not an interaction between NC and HIV status, permitting use of a combined model. For clinical relevance, we also provided separate models of the relationship between NC and cIMT. The study was able to detect an approximate 9-μm change in cIMT for each 1-cm change in NC, with power of 0.8 in the HIV and non-HIV groups. All analyses were performed using SAS JMP (SAS Institute, Cary, NC). Results are means ± SEM.

**RESULTS**

**Demographic data**

HIV-infected and control subjects were similar in age and sex (Table 1). There was no difference in racial composition of the groups (HIV, 36% Caucasian, 43% black, 16% Hispanic, 5% other; non-HIV, 38% Caucasian, 47% black, 10% Hispanic, 5% other; P = 0.18). The HIV group had a significantly higher percentage of current smokers (52 versus 26%) and previous smokers (16 versus 12%) and a higher number of lifetime pack-years (Table 1). Although known diabetes was an exclusion criterion for entry into the study, a small percentage of subjects had a fasting glucose or 2-h glucose in diabetics range (Table 1).

Among the HIV-infected group, 84% of HIV-infected subjects were currently being treated with combination ARV therapy: 45% currently on protease inhibitors (PIs), 82% on NRTIs, and 25% on non-nucleoside reverse transcriptase inhibitors (NNRTIs). See Table 1 for duration of use of each class of antiretroviral therapy.

**Metabolic parameters**

Two-hour glucose, fasting insulin, and triglycerides were all significantly higher among HIV-infected subjects compared with control subjects. In contrast, HDL cholesterol was significantly lower among HIV-infected subjects. These differences persisted when controlling for sex (see adjusted P value; Table 1).

**Anthropometric measurements**

Waist-to-hip ratio (WHR) and VAT were significantly higher among HIV-infected subjects, whereas SAT and arm circumference were significantly lower among HIV-infected subjects. These differences persisted when controlling for sex between the groups (Table 1). NC was similar between groups and was not significantly affected by HIV status when controlling for age, race, and sex (P = 0.67 for HIV status). By design, BMI was not different between the two groups (Table 1).

**Univariate regression analysis relating cardiometabolic parameters to NC**

In univariate regression analysis among all subjects, NC was significantly related to numerous body composition measures and metabolic parameters (Table 2). In a subset for which exercise data were available (n = 199), physical activity was not related to NC (P = 0.38). In the HIV group, with the exception of triglycerides, NC was related to the same parameters as the entire cohort. Among non–HIV-infected subjects, NC was also related to the same parameters as in the entire cohort. Duration of HIV infection (r = 0.16, P = 0.03) and cumulative exposure to NRTIs (r = 0.15, P = 0.05) did show an association with NC in univariate analysis, but neither was significant when controlling for age. NC was not significantly associated with cumulative exposure to PIs (P = 0.25) or NNRTIs (P = 0.10). CD4 count was not...
Neck circumference and cardiometabolic risk

Table 1—Demographic and clinical characteristics of the study population

| Parameter                        | Group                    |                   | P value | Adjusted P value* |
|----------------------------------|--------------------------|-------------------|---------|-------------------|
|                                  | HIV-infected             | HIV-negative      |         |                   |
| N                                | 174                      | 154               | 0.43    |                   |
| Demographics                     |                          |                   |         |                   |
| Age (years)                      | 44 ± 1                   | 43 ± 1            | 0.08    |                   |
| Sex (n [%])                      |                          |                   |         |                   |
| Male                             | 43 (25)                  | 26 (17)           | 0.12    |                   |
| Female                           | 131 (75)                 | 128 (83)          |         |                   |
| Race (n [%])                     |                          |                   |         |                   |
| Caucasian                        | 89 (51)                  | 92 (60)           |         |                   |
| Non-Caucasian                    | 85 (49)                  | 62 (40)           |         |                   |
| Current smoking (n [%])          | 90 (52)                  | 40 (26)           | <0.0001 |                   |
| Lifetime smoking (pack-years)    | 12.1 ± 1.0               | 4.6 ± 1.1         | <0.0001 |                   |
| Diabetes (n [%])†                | 9 (6)                    | 3 (2)             | 0.10    |                   |
| HIV parameters                   |                          |                   |         |                   |
| Duration HIV (months)            | 121 ± 5                  | N/A               |         |                   |
| CD4 (n/mm³)                      | 510 ± 21                 | N/A               |         |                   |
| HIV viral load (copies/mL)       | 6,075 ± 1,320            | N/A               |         |                   |
| Duration PI use (months)         | 30 ± 3                   | N/A               |         |                   |
| Duration NRTI use (months)       | 59 ± 4                   | N/A               |         |                   |
| Duration NNRTI use (months)      | 16 ± 2                   | N/A               |         |                   |
| Metabolic parameters             |                          |                   |         |                   |
| Blood pressure (mmHg)            |                          |                   |         |                   |
| Systolic                          | 116 ± 1                  | 114 ± 1           | 0.24    | 0.43              |
| Diastolic                         | 74 ± 1                   | 72 ± 1            | 0.05    | 0.12              |
| Fasting glucose (mg/dL)          | 87 ± 1                   | 84 ± 1            | 0.04    | 0.07              |
| 2-h glucose (mg/dL)              | 128 ± 4                  | 108 ± 3           | <0.0001 | <0.0001           |
| Fasting insulin (µU/mL)          | 8.9 ± 0.7                | 5.7 ± 0.3         | 0.0002  | <0.0001           |
| Cholesterol (mg/dL)              |                          |                   |         |                   |
| Total                             | 183 ± 3                  | 176 ± 3           | 0.12    | 0.07              |
| LDL                               | 109 ± 3                  | 105 ± 3           | 0.32    | 0.27              |
| HDL                               | 46 ± 1                   | 56 ± 1            | <0.0001 | <0.0001           |
| Triglycerides (mg/dL)            | 149 ± 11                 | 79 ± 3            | <0.0001 | <0.0001           |
| Average cIMT (mm)                | 0.68 ± 0.01              | 0.66 ± 0.01       | 0.26    | 0.48              |
| Body composition parameters      |                          |                   |         |                   |
| BMI (kg/m²)                       | 26.6 ± 0.4               | 27.5 ± 0.4        | 0.11    | 0.10              |
| WHR                              | 0.93 ± 0.01              | 0.86 ± 0.01       | <0.0001 | <0.0001           |
| SAT area (cm²)                   | 251 ± 10                 | 284 ± 11          | 0.02    | 0.04              |
| VAT area (cm²)                   | 109 ± 5                  | 87 ± 5            | 0.001   | 0.004             |
| Arm fat by DEXA (kg)             | 2.6 ± 0.1                | 3.0 ± 0.1         | 0.005   | 0.01              |
| Trunk fat by DEXA (kg)           | 11.6 ± 0.4               | 11.6 ± 0.4        | 0.91    | 0.94              |
| Iliac waist (cm)                 | 94 ± 1.0                 | 91 ± 1.1          | 0.09    | 0.15              |
| NC (cm)                          | 37.0 ± 0.3               | 36.4 ± 0.3        | 0.50    | 0.80              |
| Arm circumference (cm)           | 31.0 ± 0.4               | 32.1 ± 0.3        | 0.03    | 0.008             |

Data are reported as means ± SEM or percentage. N/A, not applicable. *P value for effect of HIV infection controlling for sex. †Diabetes diagnosed by 2-h OGTT, fasting blood glucose ≥126, and/or 2-h blood glucose ≥200.

significantly associated with NC on univariate analysis (P = 0.17). HIV viral load was also not associated with NC (P = 0.89).

Univariate regression analysis relating cardiometabolic parameters to cIMT

In univariate regression analysis among all subjects, cIMT was significantly related to age, BP, hemoglobin A1c, fasting glucose, waist circumference, WHR, BMI, VAT, smoking pack-years, and NC. It is noteworthy that dual-energy X-ray absorptiometry (DEXA) measurements of upper arm fat and trunk fat were not significantly associated with cIMT, in contrast with the highly significant relationship seen between NC and cIMT in all groups. Subgroup analysis among HIV and HIV-negative subjects is shown in Table 3.

Multivariate analysis of NC in relationship to lipid and glucose parameters

In multivariate modeling among the entire cohort, controlling for age, sex, race, HIV status, and VAT, NC was no longer a significant predictor of BP, LDL, or triglyceride (data not shown). However, NC remained a strong independent predictor of HDL (P = 0.001), glucose (P = 0.02), and insulin (P = 0.0002). There was no relationship between NC and 2-h glucose (Supplementary Table 1). When BMI was used in the model instead of VAT, results were similar (Supplementary Table 2). In subanalyses, multivariate modeling was performed separately for the HIV-infected and HIV-negative groups (Supplementary Tables 1 and 2). For the HIV-negative cohort, NC remained a significant predictor of HDL but did not significantly predict glucose or insulin. In the HIV-infected group, NC remained a significant independent predictor of HDL (P = 0.02) and fasting insulin (P = 0.002). When cumulative exposure to PI, NRTI, and NNRTI was added to the models, results were similar.

Multivariate analysis of NC in relationship to cIMT

Among the entire group of subjects, NC was also a significant predictor of average cIMT in multivariate modeling controlling for HIV status and traditional cardiovascular risk factors, including age, sex, race, pack-years of smoking, hypertension or use of antihypertensive medications, glucose, and LDL (P = 0.02 for NC; for model, R² = 0.41, P < 0.0001, Table 4). In this model, each 1-cm increase in NC was associated with a 5-µm increase in cIMT. This association remained significant when additionally controlling for VAT (P = 0.001 for NC; for model, R² = 0.42, P < 0.0001) but was no longer significant with BMI in the model rather than VAT (P = 0.90 for NC). In sensitivity analysis using only women, NC remained significantly associated with cIMT. In the subset for which physical activity was available, adding activity to the model did not change the significance of NC in relationship to cIMT (P = 0.02). In a separate analysis among non-HIV control subjects, NC was significantly associated with cIMT, controlling for traditional risk factors, including age, sex, race, smoking, hypertension, glucose, and lipids (P = 0.005 for NC; for model, R² = 0.45, P < 0.0001, Table 4) and in a model controlling for traditional risk factors and VAT (P = 0.005 for NC;
Table 2—Univariate associations between cardiometabolic parameters and NC in HIV- and non–HIV-infected individuals

| Parameter                  | Entire cohort | HIV-infected | HIV-negative |
|----------------------------|--------------|--------------|--------------|
| Age (years)                | 0.22 <0.001  | 0.20 0.008   | 0.23 <0.001  |
| Blood pressure (mmHg)      |              |              |              |
| Systolic                   | 0.25 <0.001  | 0.16 0.04    | 0.37 <0.001  |
| Diastolic                  | 0.30 <0.001  | 0.23 0.002   | 0.38 <0.001  |
| Cholesterol (mg/dL)        |              |              |              |
| Total                      | −0.001 0.98  | 0.002 0.98   | −0.02 0.84   |
| LDL                        | 0.10 0.09    | 0.07 0.38    | 0.13 0.11    |
| HDL                        | −0.35 <0.001 | −0.25 0.002  | −0.48 <0.001 |
| Triglycerides (mg/dL)      | 0.13 0.02    | 0.10 0.18    | 0.30 0.0002  |
| Hemoglobin A1c (%)         | 0.20 0.0004  | 0.16 0.04    | 0.28 0.0006  |
| Fasting glucose (mg/dL)    | 0.27 <0.001  | 0.27 0.0004  | 0.27 0.0008  |
| Fasting insulin (µU/mL)    | 0.21 0.005   | 0.18 0.03    | 0.26 0.0003  |
| 2-h glucose (mg/dL)        | 0.02 0.73    | −0.04 0.62   | 0.09 0.31    |
| Iliac waist circumference (cm) | 0.68 <0.001 | 0.67 <0.0001 | 0.70 <0.001 |
| WHR                        | 0.51 <0.001  | 0.49 <0.0001 | 0.60 <0.0001 |
| BMI (kg/m²)                | 0.57 <0.001  | 0.58 <0.0001 | 0.57 <0.0001 |
| SAT area (cm²)             | 0.35 <0.001  | 0.36 <0.0001 | 0.35 <0.0001 |
| VAT area (cm²)             | 0.60 <0.001  | 0.53 <0.0001 | 0.69 <0.0001 |
| Arm fat by DEXA (kg)       | 0.37 <0.001  | 0.41 <0.0001 | 0.35 <0.0001 |
| Trunk fat by DEXA (kg)     | 0.53 <0.001  | 0.54 <0.0001 | 0.52 <0.0001 |
| Smoking history (pack-years) | 0.08 0.17     | 0.10 0.21    | 0.03 0.76    |

*r is Pearson correlation coefficient.

for model, $R^2 = 0.45$, $P < 0.0001$). In contrast, in the analysis of the HIV-infected cohort, NC was not a significant predictor of cIMT in models controlling for traditional risk factors with or without the addition of VAT (Table 4). Similar results were seen when cumulative exposure to PI, NRTI, and NNRTI was included in the modeling (data not shown). Neither CD4+ count nor viral load was significantly associated with cIMT (data not shown).

CONCLUSIONS—Although the association between visceral obesity and cardiometabolic abnormalities is well established (2), less is known about the metabolic relevance of other upper body subcutaneous fat stores. Upper body adipose tissue is an important contributor to circulating free fatty acids (FFA) and is more lipolytically active than lower body adipose tissue (15). Because FFA concentrations are directly associated with insulin resistance (16), hepatic VLDL production (17), and endothelial dysfunction (18), upper body adipose tissue may have important cardiovascular and metabolic consequences (19). NC, as a surrogate measure of upper body adiposity, has been associated with numerous cardiovascular risk factors in the general population (20,21). Moreover, a recent analysis of the Framingham Heart Study demonstrated that NC is associated with insulin resistance, elevated BP, and dyslipidemia, independent of visceral adiposity (9).

An important and novel aspect of the current study is the significant relationship observed between NC and cIMT. Our data extend the observations of the Framingham Heart Study (9) by demonstrating that NC is associated with a direct measure of subclinical atherosclerosis, cIMT, in the general population. To our knowledge, this is the first study to assess the relationship between NC and cIMT. The relationship between NC and cIMT was independent of traditional risk factors, including smoking, hypertension, LDL, glucose, and visceral adiposity. The significant independent relationship between cIMT and NC seen among all subjects held in a multivariate regression analysis limited to HIV-negative patients. However, the relationship did not remain significant when controlling for BMI instead of VAT, which may be the result of significant covariance of NC and BMI. These data suggest that NC may indicate a high-risk adipose depot in relationship to atherosclerotic indexes.

In subanalysis of the HIV-infected cohort alone, NC was not a significant predictor of cIMT after controlling for traditional risk factors. The risk factors for CVD in HIV infection are numerous and include traditional factors as well as lifestyle factors and inflammatory and immune status as characterized by markers such as o-dimer (22), monocyte chemotactant protein (MCP)-1 (23), and decreased CD4+ count (24). The nontraditional factors contributing to CVD in this population may explain the lack of association between cIMT and NC, in contrast with the significant relationship seen in the HIV-negative group. Moreover, NC may be a more stable fat depot, less affected by exposure to chronic ARVs than other fat depots; changes in these other depots, such as VAT, might drive cIMT changes to a greater degree in the HIV population.

In HIV infection, an association between upper trunk fat and insulin resistance has been described (8), but the relationship between NC per se and metabolic variables has not been characterized. We now show that among both HIV and non-HIV groups, NC is strongly associated with cardiometabolic risk factors, including HDL and fasting insulin. It is noteworthy that NC remains strongly and significantly associated with these risk factors in models controlling for VAT or BMI, demonstrating the importance of upper body fat, distinct from visceral fat, as a contributor to dyslipidemia and insulin resistance. The lipolytic activity of upper body fat may mediate this relationship with lipid metabolism and glucose homeostasis. Studies of regional lipolysis have demonstrated that, in the postabsorptive state, ~50% of circulating FFA is from nonsubcutaneous upper body fat stores (15). Of note, arm circumference did not demonstrate the same associations with lipid and glucose parameters as NC in our cohort (data not shown), possibly because arm circumference may be more reflective of lean mass as well as adiposity.

Our study has limitations. First, NC is a measure of both adipose and lean tissue, thus not a direct measure of adiposity, although our data suggest that it is a good surrogate measure of adiposity and, in fact, much more significantly related to cIMT than other measures of upper body adiposity. There is variability
Neck circumference and cardiometabolic risk

Table 4—Multivariate modeling of the relationship of traditional risk factors and NC to average cIMT

| Parameter                  | Entire cohort | HIV-infected | HIV-negative |
|----------------------------|--------------|--------------|--------------|
|                            | β-Estimate   | P value      | β-Estimate   | P value      | β-Estimate   | P value      |
| Age (years)                | 0.006        | <0.0001      | 0.008        | <0.0001      | 0.004        | 0.0002       |
| Sex (male)                 | 0.000        | 1.00         | 0.004        | 0.77         | −0.011       | 0.41          |
| Race (Caucasian)           | −0.013       | 0.04         | −0.015       | 0.11         | −0.013       | 0.11          |
| HIV (HIV negative)         | 0.008        | 0.20         | N/A          | N/A          | N/A          | N/A           |
| Smoking pack-years         | 0.002        | <0.0001      | 0.002        | 0.008        | 0.003        | <0.0001      |
| Hypertension or antihypertensive use | 0.031 | 0.0001 | 0.019 | 0.09 | 0.048 | <0.0001 |
| LDL (mg/dL)                | 0.000        | 0.53         | 0.000        | 0.98         | 0.000        | 0.14          |
| Fasting glucose (mg/dL)    | 0.000        | 0.74         | 0.000        | 1.00         | 0.000        | 0.69          |
| NC (cm)                    | 0.005        | 0.02         | 0.003        | 0.39         | 0.009        | 0.005         |

For entire cohort, $R^2 = 0.41$ and $P < 0.0001$. For HIV-infected group, $R^2 = 0.41$ and $P < 0.0001$. For HIV-negative group, $R^2 = 0.45$ and $P < 0.0001$. 

Table 3—Univariate associations between cardiometabolic parameters and cIMT in HIV- and non–HIV-infected individuals

| Parameter                  | Entire cohort | HIV-infected | HIV-negative |
|----------------------------|--------------|--------------|--------------|
|                            | r*           | P value      | r*           | P value      | r*           | P value      |
| Age (years)                | 0.53         | <0.0001      | 0.57         | <0.0001      | 0.49         | <0.0001      |
| Blood pressure (mmHg)      |              |              |              |              |              |              |
| Systolic                   | 0.35         | <0.0001      | 0.35         | <0.0001      | 0.33         | <0.0001      |
| Diastolic                  | 0.30         | <0.0001      | 0.25         | 0.0009       | 0.34         | <0.0001      |
| Cholesterol (mg/dL)        |              |              |              |              |              |              |
| Total                      | 0.06         | 0.32         | −0.03        | 0.69         | 0.18         | 0.03         |
| LDL                        | 0.07         | 0.22         | −0.06        | 0.47         | 0.24         | 0.003        |
| HDL                        | −0.04        | 0.50         | 0.14         | 0.07         | −0.21        | 0.01         |
| Triglycerides (mg/dL)      | −0.006       | 0.92         | −0.08        | 0.32         | 0.17         | 0.04         |
| Hemoglobin A1c (%)         | 0.22         | <0.0001      | 0.22         | 0.004        | 0.26         | 0.0014       |
| Fasting glucose (mg/dL)    | 0.20         | 0.0055       | 0.15         | 0.06         | 0.25         | 0.003        |
| Fasting insulin (µU/mL)    | 0.03         | 0.63         | 0.004        | 0.96         | 0.01         | 0.88         |
| 2-h Glucose (mg/dL)        | 0.10         | 0.10         | 0.08         | 0.35         | 0.10         | 0.22         |
| Iliac waist circumference (cm) | 0.24   | <0.0001      | 0.19         | 0.01         | 0.30         | 0.0002       |
| WHR                        | 0.21         | 0.0001       | 0.09         | 0.26         | 0.34         | <0.0001      |
| BMI (kg/m²)                | 0.16         | 0.004        | 0.15         | 0.05         | 0.19         | 0.02         |
| SAT area (cm²)             | 0.10         | 0.07         | 0.05         | 0.48         | 0.17         | 0.03         |
| VAT area (cm²)             | 0.16         | 0.005        | 0.04         | 0.64         | 0.30         | 0.0001       |
| Arm fat by DEXA (kg)       | 0.05         | 0.36         | 0.04         | 0.57         | 0.09         | 0.29         |
| Trunk fat by DEXA (kg)     | 0.08         | 0.13         | 0.03         | 0.66         | 0.15         | 0.06         |
| Smoking history (pack-years) | 0.39   | <0.0001      | 0.39         | <0.0001      | 0.38         | <0.0001      |
| NC (cm)                    | 0.25         | <0.0001      | 0.21         | 0.006        | 0.31         | 0.0001       |

* r is Pearson correlation coefficient.

in measurement of NC, but we have shown this to be small. There are limited data on the effects of racial differences and lifestyle factors on measurements of NC, and further data are needed in this regard. Inclusion of patients with known diabetes might have enhanced our ability to describe associations between body composition and glucose parameters across a broader disease spectrum. However, by excluding subjects with known diabetes, we avoided recruiting subjects in whom our ability to see a strong relationship with NC might have been confounded by a high prevalence of diabetes. A small number of subjects met criteria for diabetes on glucose tolerance testing, and these data were included in the analysis. Further studies examining these specific relationships in large populations with diabetes are now needed. NC may be a strong predictor of obstructive sleep apnea (25). We cannot exclude the possibility that the metabolic consequences of obstructive sleep apnea may confound the relationship between NC and metabolic parameters. Longitudinal data relating change in NC to cardiovascular risk will be useful. Finally, cIMT may be more difficult to measure in subjects with increasing neck girth, but we show similar variance in the measure of cIMT across NC quartiles, suggesting that our results were not affected in this way.

Overall, our data highlight the metabolic importance of upper body adiposity, as measured by NC, in both HIV-infected and HIV-negative individuals. In particular, NC is a strong predictor of measures of insulin resistance and HDL cholesterol, and, in HIV-negative individuals, is also significantly associated with cIMT. These data reinforce the notion that upper body fat is particularly and uniquely linked to metabolic abnormalities, independent of other measures of abdominal adiposity such as VAT.
rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92:2506–2512.
2. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007;116:39–48.
3. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest 2004;113:1582–1588.
4. Shlay JC, Visnegarwala F, Bartsch G, et al.; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Body composition and metabolic changes in antiretroviral-naïve patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr 2005;38:147–155.
5. Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008,118:198–210.
6. Wohl D, Scherzer R, Heymsfield S, et al.; FRAM Study Investigators. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 2008;48:44–52.
7. Guaraldi G, Stentarelli C, Zona S, et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis 2010;208:222–227.
8. Grunfeld C, Rimland D, Gibert CL, et al. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr 2007;46:283–290.
9. Preis SR, Massaro JM, Hoffmann U, et al. Neck circumference as a novel measure of cardiometabolic risk: the Framingham Heart study. J Clin Endocrinol Metab 2010;95:3701–3710.
10. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2003;39:44–54.
11. Borkan GA, Gerzof SG, Robbins AH, Hults DE, Silbert CK, Silbert JE. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 1982;36:172–177.
12. Kriska AM, Knowler WC, LaPorte RE, et al. Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians. Diabetes Care 1990;13:401–411.
13. Chan RC, Kauflhold J, Hemphill LC, Lees RS, Karl WC. Anisotropic edge-preserving smoothing in carotid B-mode ultrasound for improved segmentation and intima-media thickness (IMT) measurement. Comput Cardiol 2000;27:37–40.
14. Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol 2010;55:1600–1607.
15. Jensen MD. Gender differences in regional fatty acid metabolism before and after meal ingestion. J Clin Invest 1995;96:2297–2303.
16. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983;72:1737–1747.
17. Kissebah AH, Alfarai S, Adams PW, Wynn V. Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. Diabetologia 1976;12:563–571.
18. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997;100:1230–1239.
19. Thamer M, Machann J, Staiger H, et al. Interscapular fat is strongly associated with insulin resistance. J Clin Endocrinol Metab 2010;95:4736–4742.
20. Yang L, Samarasinghe YP, Kane P, Amiel SA, Aylwin SJ. Visceral adiposity is closely correlated with neck circumference and represents a significant indicator of insulin resistance in WHO grade III obesity. Clin Endocrinol (Oxf) 2010;73:197–200.
21. Ben-Noun L, Laor A. Relationship of neck circumference to cardiovascular risk factors. Obes Res 2003;11:226–231.
22. Ford ES, Greenwald JH, Richterman AG, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010;24:1509–1517.
23. Lo J, Abbara S, Shituman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010;24:243–253.
24. Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System. J Acquir Immune Defic Syndr 2010.
25. Brown TT, Patil SP, Jacobson LP, et al. Anthropometry in the prediction of sleep disordered breathing in HIV-positive and HIV-negative men. Antivir Ther 2010;15:651–659.